-+ 0.00%
-+ 0.00%
-+ 0.00%

Evaxion Awarded Gates Foundation Grant To Advance AI-Powered Vaccine Design Targeting Global Polio Eradication, Using Its AI-Immunology Platform To Develop Novel Antigen Constructs Amid Ongoing Risk Of Global Resurgence; No Financial Terms Disclosed

Benzinga·06/03/2025 13:19:24
Listen to the news
  • Evaxion awarded a grant from the Gates Foundation
  • Grant funds research aimed at ultimately eradicating polio, a highly infectious viral disease
  • Evaxion will apply its leading AI-Immunology™ platform to identify and combine various antigens to combat the virus and develop design options for a potential new vaccine construct
  • Risk of a global polio resurgence and health crisis remain, thus a new vaccine concept is warranted

COPENHAGEN, Denmark, June 3, 2025 - Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, receives funding support from the Gates Foundation to help the world eradicate polio (poliomyelitis) by exploring design options for a new and unique vaccine.

Despite polio vaccines being available for decades, the highly infectious viral disease is yet to be completely eradicated, meaning that the risk of a global polio resurgence and health crisis remain. Thus, a new vaccine concept could increase the possibility of eradicating the virus once and for all.

The project will combine Evaxion's leading and clinically validated AI-Immunology™ platform with support from the Gates Foundation. Evaxion will deploy AI-Immunology™ to identify and combine various antigens to combat the virus. Based on these findings, a number of new antigen constructs will be designed for selection and validation. The work will be supported by the grant from the Gates Foundation, meaning there will be no financial cost for Evaxion.